Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Open in API
Filings indexed 1,223 across all filing types
Latest filing 2024-12-30 Interim / Quarterly Rep…
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
REPORT OF FOREIGN PRIVATE ISSUER
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filing by XTL Biopharmaceuticals Ltd., which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. It includes detailed financial results for the nine months ended September 30, 2024, including unaudited condensed consolidated financial statements and comprehensive loss statements. The document also discusses recent acquisitions, private placements, and operational impacts due to geopolitical events. The presence of detailed financial data and analysis for a period shorter than a full fiscal year (nine months) indicates this is an interim or quarterly report. Form 6-K is commonly used by foreign private issuers to report interim financial results and other material information. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2024-12-30 English
REPORT OF FOREIGN PRIVATE ISSUER
Interim / Quarterly Report Classification · 100% confidence The document is a Form 6-K filed by a foreign private issuer, XTL Biopharmaceuticals Ltd., with the SEC. It contains detailed financial results for the six months ended June 30, 2024, including unaudited condensed consolidated financial statements (statements of financial position and comprehensive loss), discussion of business operations, acquisition details, and other operational updates. The presence of substantive financial data and analysis for a half-year period indicates this is an interim or quarterly report. The document is not merely an announcement or a certification but includes actual financial statements and management commentary. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2024-12-30 English
Form 6-K- As previously disclosed, on November 11, 2024- entered into a settlement agreement-
Regulatory Filings Classification · 98% confidence The document explicitly states it is a "Form 6-K, Report of Foreign Private Issuer" filed pursuant to the Securities Exchange Act of 1934 for the month of November, 2024. Form 6-K is used by foreign private issuers to report material information not required to be reported under the home country's requirements or furnished to the SEC. This type of filing is a periodic or current report that does not fit the specific definitions of 10-K (Annual Report) or IR (Interim/Quarterly Report). Since Form 6-K is a general regulatory filing requirement for foreign private issuers, and there is no specific code for 6-K, the most appropriate fallback category is 'Regulatory Filings' (RNS), as it covers miscellaneous SEC filings that don't fit other specific categories like earnings releases (ER) or proxy statements (DEF 14A). The document length is substantial enough (5479 chars) that it is the report itself, not just an announcement of a report.
2024-11-20 English
Form 6-K- As previously disclosed, on November 11, 2024- entered into a settlement agreement-
Report Publication Announcement Classification · 98% confidence The document is an 'Immediate Report' filed with the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE). It explicitly states, 'Attached hereto is a report on *ea022190601_6k_xtlbio_AsFiled_isa.pdf*'. The filename extension '.pdf' and the structure strongly suggest this document is an announcement *about* an attached filing, rather than the full filing itself. Furthermore, the reference to '6k' in the filename often correlates with SEC Form 6-K, which is typically used by foreign private issuers for material events. Since 6-K is not an explicit category, and this document serves as a notification that a report has been published, it fits the criteria for a Report Publication Announcement (RPA) based on the 'MENU VS MEAL' rule, as it announces the availability of another document. If the attached document were provided, it might be classified as 10-K (if annual) or IR (if quarterly/interim), but this wrapper document is an RPA.
2024-11-20 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, XTL Biopharmaceuticals Ltd., with the SEC. It reports a corporate action involving a settlement agreement and adjustment of shares and warrants related to a subsidiary. The document includes a resolution by the Board of Directors and references the company's website for the full text of the resolution. It does not contain financial statements or detailed financial analysis. The document is 5809 characters long, which is relatively short and primarily serves as a regulatory announcement of a corporate event rather than a full report. It is not an annual or interim report, earnings release, or detailed management discussion. It is also not a certification or attestation. Therefore, it fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2024-11-19 English
Resolution of the controversy arisen between the Company and its subsidiary in connection to the immediate Report dated 15.10.24
Regulatory Filings Classification · 98% confidence The document explicitly identifies itself as a "Form 6-K, Report of Foreign Private Issuer" filed with the SEC for the month of November, 2024. Form 6-K is used by foreign private issuers to report material information that is not otherwise required to be reported on a schedule 13D or 13G or Form 20-F. This type of filing is a mandatory, periodic disclosure that does not fit neatly into the specific categories like 10-K (Annual Report), ER (Earnings Release), or DEF 14A (Proxy/Remuneration). Since it is a general, required regulatory filing for material events not covered by other specific codes, the most appropriate classification is the general regulatory filing fallback category, RNS (Regulatory Filings). The document length (6413 chars) is substantial enough to be the report itself, not just an announcement of a report.
2024-11-12 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.